LUCD (Lucid Diagnostics) Growth Rank: 0 (As of Jul. 11, 2026)


LUCD Lucid Diagnostics Inc LUCD
20 GF Score
Price $1.00
GF Value $0.82
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics Growth Rank?

Lucid Diagnostics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Lucid Diagnostics Growth Rank Related Terms

LUCD
20GF Score
Lucid Diagnostics Inc LUCD
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $1.00 is trading 22% above its estimated GF Value™ of $0.82. GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.

Key valuation signals for LUCD:

  • Growth Rank: 0
  • GF Value™: $0.82 vs. price of $1.00 (22% above fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
20GF Score

Get the complete analysis for LUCD

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price
$0.82
GF Value